POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, has announced the pricing of its public offering of 13,900,000 shares of Common Stock at a public offering price of US$9.00 per share. The gross proceeds to the Company from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately US$125 million. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 2,085,000 shares of its Common Stock. All of the shares to be sold in the offering are to be sold by POINT. The offering is expected to close on or about September 16, 2022, subject to customary closing conditions.
Latham & Watkins LLP represents the underwriters in the offering with a corporate team led by partners Nathan Ajiashvili and Peter Handrinos, with associates Katie Byun, Erin Gilgen, Paul Rafla, and Danny Shulman.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
